Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Werfen on Thursday announced a partnership agreement with Thermo Fisher Scientific for worldwide distribution of the TCAutomation laboratory automation system as part of the HemoCell Specialized Lab Automation system for hemostasis diagnostic testing.

On April 28, Lifotronic Technology Co., Ltd. released its 2022 annual report.

Lucira Health, which broke new ground in 2020 with the first rapid at-home COVID-19 test but filed for bankruptcy this year, said in a recent US Securities and Exchange Commission filing that it has been acquired by Pfizer for $36.4 million through a bankruptcy auction.

QuidelOrtho Corporation, a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the first quarter ended April 2, 2023.

Cytiva and the life sciences business of Pall Corporation have completed their integration and are now united as one business under the Cytiva brand.

On April 27, Mindray released its annual report, showing that in 2022, it achieved revenue of 30.366 billion CNY, up 20.17% year-on-year, net profit attributable to shareholders of the listed company was 9.607 billion CNY, up 20.07% year-on-year; net cash flow from operating activities was 12.141 billion CNY, up 34.92% year-on-year, and basic earnings per share was 7.94 CNY.

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2023.

Quest Diagnostics and Haystack Oncology said Thursday that they have reached a definitive agreement for Quest to acquire Haystack for up to $450 million in cash.

On the evening of April 25, BGI Genomics released its first quarterly financial results for 2023.

As expected, significantly lower demand for COVID-19 tests leads to a decrease in Group sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%.